InvestorsHub Logo
icon url

postes

04/20/21 8:46 AM

#336081 RE: Lrich #336079

I stand corrected...thank you.....I still stand by a large cash burn this year of a min. Of 150M....the new ceo may not be in favor of a staggered approach to rolling out the EU....what the say about having enough cash is a forward looking statement and is not trustworthy....
icon url

hamkypamky

04/20/21 10:22 AM

#336090 RE: Lrich #336079

You are correct.

JT was an excellent bookkeeper.

He was however, a poor sales lead and a terrible hype man.

Hence stagnantion in sales and a lack of self promotion in the stock due to sandbagging and ultra conservatism.

A change is welcome indeed.

However, legal failures aside (which I blame on management in some part especially filing in the 9th circuit), management of the company has actually been reasonable.

Not good, but reasonable.

Without Du and Covid, i do believe Vascepa wales would have topped $1B or thereabouts in the US by run rate already. We certainly were on track pre covid.

Du debacle (insurers preferring generic or dropping coverage) and covid (fewer tests, less access to cardios and GPs) put paid to that.
icon url

sts66

04/20/21 6:26 PM

#336161 RE: Lrich #336079

Postes, I stand corrected - looks like AMRN did indeed have $200M accounts receivable as on 12/31/20, 25% higher than they had in 2019 - and that's a frigging ENORMOUS number, 1/3 of actual revenue! WTF is going on here?